Unique, Chemistry-Driven Approach
Developing novel Microbiome Metabolic Therapies (MMT™) to drive functional outputs of the microbiome organ
Developing novel Microbiome Metabolic Therapies (MMT™) to drive functional outputs of the microbiome organ
Potential to be faster and more cost efficient
Candidates addressing a variety of diseases and conditions with high unmet needs
Committed to scientific innovation, transforming lives and fostering a strong culture
President & Chief Executive Officer
Alison Lawton has served as Kaleido’s Chief Executive Officer, President and as a member of the Board of Directors since August 2018, after initially joining the company as President and Chief Operating Officer in December 2017. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, she was COO at Aura Biosciences, and previously held the same role at X4 Pharmaceuticals and OvaScience. Ms. Lawton spent more than 20 years at Genzyme Corporation and subsequently at Sanofi following its acquisition of Genzyme. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics, and cell therapy and regenerative medicine franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years in the U.K. at Warner-Lambert/Parke-Davis. She previously served two terms as the industry representative on the Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. Ms. Lawton earned her Bachelor of Science degree in Pharmacology from King’s College London.
Chief Medical Officer and Head of Research & Development
Katharine Knobil joined Kaleido in December 2018 as Chief Medical Officer and Head of Research & Development. Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline (GSK), most recently serving as the corporate CMO, overseeing medical affairs, health outcomes, global clinical safety and medical governance across the pharmaceutical, vaccines, and consumer businesses. Previously she was CMO for Pharmaceuticals at GSK from 2015 to 2017, and prior to that was senior vice president, value evidence and outcomes. Dr. Knobil first joined GSK in 1997 as a research physician in respiratory clinical development, and subsequently held a number of roles, including leading the European respiratory clinical team, and building the late-stage clinical development for all therapeutic areas in China. Dr. Knobil was recently named one of 2018's Fiercest Women in Life Sciences by FiercePharma. She has served on the Board of Directors of the National Health Council and has been active with the National Academies of Sciences, Engineering, and Medicine, and the Patient Centered Outcomes Research Institute. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southwestern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.
Chief Scientific Officer
Dr. van Hylckama Vlieg has served as Kaleido's Chief Scientific Officer since July 2019. Dr. van Hylckama Vlieg has 25 years of experience leading teams and R&D programs in gut microbiology, probiotics and live biotherapeutics, and industrial biotechnology in industry and academia. Most recently, he served as Vice President for Microbiome and Human Health Innovation at Chr. Hansen in Denmark, responsible for new strain development for probiotic and therapeutic application, spanning discovery to clinical development and novel technology platforms. Previously, Dr. van Hylckama Vlieg worked at Danone Research and in several roles at NIZO Food Research. He completed his Ph.D. and post-doc in biochemistry at the University of Groningen in the Netherlands.
Chief Business Officer
Clare Fisher has served as Kaleido’s Chief Business Officer since April 2019. Ms. Fisher has more than 20 years of experience in healthcare, including leadership roles in corporate and business development. Most recently, she was Group Vice President, Global Head of Transactions and Business Development and Interim Head of Corporate Development at Shire plc (now Takeda). While at Shire, Ms. Fisher led a global team across therapeutic areas, managing in-licensing agreements, asset collaborations, divestments, and M&A transactions. Previously, she held senior roles in business development at Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation. Ms. Fisher holds a B.S. in Biochemistry from the University of Bath, as well as an M.B.A. from Henley Management College in the U.K.
General Counsel and Corporate Secretary
Jerald Korn has served as Kaleido’s General Counsel and Corporate Secretary since July 2019. Prior to joining Kaleido, Mr. Korn held several leadership positions of increasing responsibility at TESARO, Inc., serving most recently as Senior Vice President, Chief Legal and Administrative Officer. In this role, he managed a team of more than 30 employees across legal, compliance, government affairs, corporate communications, patient advocacy and government price reporting. In addition to implementing TESARO’s compliance program, Mr. Korn was involved in Board governance, public reporting and executing various licensing and transaction agreements. Previously, he was Associate General Counsel, Commercial and Healthcare at Cubist Pharmaceuticals, where he was responsible for all commercial and healthcare regulatory matters, including the oversight of four marketed products with annual sales in excess of $1 billion. Prior to Cubist, Mr. Korn served as Deputy Chief Compliance Officer at Millennium Pharmaceuticals and held several senior positions at AMAG Pharmaceuticals, Inc., including Vice President, Assistant General Counsel & Chief Compliance Officer. Mr. Korn began his career as an associate at the law firm Ropes & Gray. Mr. Korn earned his bachelor’s degree in economics from Harvard University and his J.D. from Boston University School of Law. Mr. Korn serves on the Board of Trustees for Solomon Schechter Day School of Greater Boston and was named to Boston Business Journal’s 2018 40 Under 40 list.
Chief Financial Officer
William Duke has served as Kaleido’s Chief Financial Officer since November 2019. He joined Kaleido from Pulmatrix, Inc., a Nasdaq-listed, clinical-stage pulmonary therapeutics company where he was CFO. There, he oversaw the company’s financial strategy, helped negotiate the company’s first product partnership, and led the successful completion of several public offerings. Prior to Pulmatrix, he served as CFO of Valeritas, Inc., a commercial-stage medical technology company, where he led a private financing round, recapitalized the company, and was responsible for the strategic planning, development and leadership of the corporate finance function. Mr. Duke also was senior director of finance at Genzyme Corporation, helping in the sale of the company to Sanofi, and director of finance/accounting at Haemonetics Corporation. Earlier in his career he held CFO positions at G8wave, an integrated media company focused on mobile platforms, and OTF Group, Inc. a business strategy consulting firm. Mr. Duke earned his B.S. in Business Administration from Stonehill College, an M.B.A. from Bentley University, and is a certified public accountant.
Senior Vice President, Regulatory Affairs & Quality
Susan Stewart has served as Kaleido's Senior Vice President, Regulatory Affairs & Quality since April 2018. Ms. Stewart has worked for more than 25 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. Previously, in addition to being an independent regulatory consultant for several years, she was senior vice president of regulatory affairs, quality, and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent more than 10 years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs. She received her J.D. from Concord Law School at Purdue University Global and her B.A. from the University of Massachusetts.
Senior Vice President, Human Resources
Wendy Arnold has served as Kaleido's Senior Vice President, Human Resources since January 2018. Ms. Arnold brings more than 20 years of experience in human resources to Kaleido, including extensive work in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Arnold was head of the HR business partnership function at Moderna Therapeutics, and helped lead the HR organization during a period of significant growth, including implementing talent and engagement initiatives, compensation framework and benefits program enhancements. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics) where she was responsible for building and developing the HR infrastructure for the company’s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.
Vice President, Technical Operations
Kimberly Hocknell has served as Kaleido’s Vice President, Technical Operations since November 2019, and previously served as our Senior Director of External Manufacturing. Ms. Hocknell brings to Kaleido extensive expertise in planning and execution throughout the product lifecycle and more than 25 years’ experience in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Hocknell held roles in chemistry, manufacturing, and controls at LFB USA, Biogen, and Genzyme Corporation (now Sanofi Genzyme). Ms. Hocknell earned her M.B.A. in finance and entrepreneurship from the Simon School of Management at the University of Rochester and her B.A. in biology from Hartwick College.
Nutrition Advisor
Dr. Miller advises Kaleido on its nutritional research and development, following a successful 30 year career at Abbott Nutrition. Dr. Miller was responsible for global pediatric, adult, and performance nutrition product development, innovation, new ventures, medical safety, clinical and preclinical research as the Divisional Vice President of R&D, Scientific and Medical Affairs at Abbott Nutrition, and was part of the Executive team managing the $7 billion nutrition business. He was an architect of the global expansion of Abbott Nutrition, establishing R&D Centers in Singapore, Shanghai, China and Bangalore, India. Dr. Miller was co-chair of the Abbott Scientific Governing Board from 2013-2016, overseeing talent development and program efforts of Abbott’s 2,500 scientists for all Abbott Laboratories divisions. Miller holds a Ph.D. in Nutritional Biochemistry from the University of Wisconsin-Madison, and completed a Staff fellowship at the National Institute of Health.
Executive Chair of Kaleido
Mike Bonney is Executive Chair of Kaleido's Board of Directors, and served as CEO from June 2017 until August 2018. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company, and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director. Bonney also chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics. He is a member of a number of other boards, including Celgene Corporation, Sarepta Therapeutics, and Syros Therapeutics. Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.
Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology, Princeton University
Bonnie Bassler, Ph.D., is Chair of the Department of Molecular Biology and the Squibb Professor of Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. She previously served as the President of the American Society for Microbiology, and on the Boards of the American Association for the Advancement of Science, the National Science Foundation and also chaired the Board of the American Academy of Microbiology. Dr. Bassler has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society. She is the recipient of the MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her B.S. from the University of California, Davis, and her Ph.D. in Biochemistry from Johns Hopkins University.
Co-Founder and General Partner at Bow Capital
Grady Burnett is Co-Founder and General Partner at Bow Capital, an early stage venture capital firm he started in July 2016. Previously, he served as Chief Operating Officer of Flurry, Inc., a mobile analytics, monetization and advertising company. Mr. Burnett previously served as Vice President, Global Sales and Operations at Facebook, Inc., Director, North American Sales and Operations for Google, and Vice President, North American Sales, at DoubleClick. He serves on the Boards of East Palo Alto Tennis and Tutoring and Menlo School. Mr. Burnett is a graduate of the University of Michigan and received his M.B.A. from Harvard Business School.
President & Chief Executive Officer of Kaleido
Alison Lawton has served as Kaleido’s Chief Executive Officer, President and as a member of the Board of Directors since August 2018, after initially joining the company as President and Chief Operating Officer in December 2017. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, she was COO at Aura Biosciences, and previously held the same role at X4 Pharmaceuticals and OvaScience. Ms. Lawton spent more than 20 years at Genzyme Corporation and subsequently at Sanofi following its acquisition of Genzyme. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics, and cell therapy and regenerative medicine franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years in the U.K. at Warner-Lambert/Parke-Davis. She previously served two terms as the industry representative on the Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. Ms. Lawton earned her Bachelor of Science degree in Pharmacology from King’s College London.
Executive Partner, Flagship Pioneering
Theo Melas-Kyriazi has served as an Executive Partner at Flagship Pioneering since April 2019. He is also Chief Financial Officer of Levitronix Technologies, Inc., a leader in magnetically levitated pumps for microelectronics and bioprocessing applications. He spent nearly two decades at Thermo Electron Corporation (now Thermo Fisher Scientific) in a variety of roles, including six years as CFO. There, he was instrumental in raising $2 billion in equity and convertible debt and executed Initial Public Offerings (IPOs) for five of Thermo Fisher’s subsidiary companies. Mr. Melas-Kyriazi has served on the Boards of Directors of multiple private and public life science companies and is currently a Director of Evelo Biosciences, Inc. (Nasdaq: EVLO). He holds a Bachelor’s degree in economics from Harvard University and an M.B.A. from Harvard Business School.
Chief Digital Transformation Officer and Vice President, Strategy at Boston Children’s Hospital
Jean Mixer has more than 25 years of experience in healthcare and is currently Chief Digital Transformation Officer and Vice President, Strategy at Boston Children’s Hospital. Previously, she launched and ran her own consulting firm, and served for more than a decade as a partner at the Boston Consulting Group. Ms. Mixer has experience across the healthcare industry, including working with executive management and Boards of leading academic medical centers, integrated healthcare delivery networks, payers, pharmacy/PBMs and biopharmaceutical and medical device companies. She began her career as an officer at J.P. Morgan in New York. She previously served on the Board of Directors of two public companies, Cambridge Trust and NxStage Medical, which was acquired by Fresenius Medical Care for $2 billion in February 2019. She received a master’s degree in Management from the Kellogg School of Management.
President & Chief Executive Officer of Aeglea BioTherapeutics
Anthony G. Quinn, M.D., Ph.D., is President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. Prior to that, he worked as a private consultant for IDBioPharm Consulting LLC. Previously, Dr. Quinn served as Executive Vice President, Head of Research & Development and Chief Medical Officer for Synageva BioPharma Corp., which was acquired by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quinn previously served as worldwide Head of Clinical Research and Exploratory Development for inflammatory diseases at Roche. Dr. Quinn received his BMSc. in general pathology and his MB ChB (M.D.) from the University of Dundee, UK. and his Ph.D. in cancer research from the University of Newcastle in Tyne, UK. He completed a postdoctoral fellowship at University of California, San Francisco before being appointed Professor of Dermatology at Barts & The London School of Medicine, UK. Dr. Quinn is a fellow of the Royal College of Physicians London.
Co-Founder of Kaleido & Partner of Flagship Pioneering
Geoffrey von Maltzahn, Ph.D., is a co-founder and Director of Kaleido, and has been a Partner at Flagship Pioneering since 2009. He has co-founded multiple other companies, including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals. Dr. von Maltzahn currently serves as Chief Innovation Officer for Indigo, where he led the creation of the world’s largest plant microbiome database and development of the company’s first commercial products. He is an inventor on more than 200 patents and patent applications in biotech, nutrition and microbiome-based technologies and has been recognized with numerous awards, including the prestigious Lemelson-MIT student prize, given to the most innovative student at MIT. Dr. von Maltzahn’s innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. Dr. von Maltzahn was awarded a Ph.D. in biomedical engineering and medical physics from MIT, a M.S. in bioengineering from the University of California, San Diego, and an S.B. in chemical engineering from MIT.
Chair of Kaleido’s Scientific Advisory Board, Professor Emeritus and former Chair, Department of Medicine at University College Cork (UCC), National University of Ireland
Fergus Shanahan is Chair of Kaleido’s Scientific Advisory Board, Professor Emeritus and former Chair, Department of Medicine at University College Cork (UCC), National University of Ireland. Dr. Shanahan was the foundation director of the APC Microbiome Institute 2003-2019 (now known as APC Microbiome Ireland) which was established with funding from Science Foundation Ireland and grants from industry and which investigates host-microbe interactions in the gut in health and disease. He is co-founder of Alimentary Health Ltd, Tucana Health and Atlantia Food Clinical Trials Ltd. Dr. Shanahan has published more than 550 scientific papers, including several on the medical humanities. His interests include mucosal immunology, gut microbiota, and inflammatory bowel disease. He holds an M.D. from University College Dublin.
President and CEO, Dana-Farber Cancer Institute
Dr. Glimcher is the President and CEO of the Dana-Farber Cancer Institute, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine, Provost for Medical Affairs of Cornell University, the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School serving as Senior Physician and Rheumatologist at Brigham and Woman’s Hospital. Dr. Glimcher received her M.D. from Harvard Medical School.
Assistant Professor in the Department of Genomic Medicine, Division of Cancer Medicine, MD Anderson Cancer Center
Dr. Jenq is an Assistant Professor in the Department of Genomic Medicine and the Department of Stem Cell Transplantation, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. His laboratory examines the impact of the microbiome on cancer treatment, focusing in particular on bone marrow transplantation and cancer immunotherapies. Data from his group and others has demonstrated that the microbiome can be a potent modulator of cancer treatment efficacy and toxicity. Using a multidisciplinary approach, Professor Jenq hopes to develop and translate strategies to target the microbiome to further increase treatment efficacy while reducing toxicities. Dr. Jenq holds an M.D. from Oregon Health and Science University
Head of the Section on Integrative Physiology and Metabolism and Past President/CEO, Joslin Diabetes Center
Dr. Kahn is a world recognized expert in diabetes and obesity research, as well as a preeminent investigator in the area of insulin signal transduction and mechanisms of altered signaling in diabetes and metabolic disease. Dr. Kahn is Senior Investigator, Head of the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. Dr. Kahn served as Research Director of the Joslin Diabetes Center from 1981 to 2000, and served as President of Joslin from 2001 to 2007. He is currently the Center’s Chief Academic Officer. He received his M.D. from the University of Louisville.
Novartis Professor of Chemistry, Massachusetts Institute of Technology
Dr. Kiessling is the Novartis Professor of Chemistry at the Massachusetts Institute of Technology (MIT) where her group focuses on using chemical biology to elucidate the biological roles of carbohydrates. She served as an American Cancer Society Postdoctoral Fellow at the California Institute Technology for two years before joining the faculty of the University of Wisconsin, Madison in 1991. She previously served as the Steenbock Professor of Chemistry, the Laurens Anderson Professor Biochemistry, and the Director of the Keck Center for Chemical Genomics. She holds a Ph.D. in chemistry from Yale University.
Professor of Internal Medicine and endocrinologist, University of Amsterdam’s Faculty of Medicine (AMC-UvA)
Dr. Nieuwdorp is a professor of Internal Medicine and endocrinologist at the University of Amsterdam’s Faculty of Medicine (AMC-UvA) and conducts research into the role of intestinal bacteria in the development of diabetes, fatty liver (steatosis) and cardiovascular disease. Through fecal transplants, Dr. Nieuwdorp investigates the causal role of intestinal bacteria that are involved in the emergence of these diseases and potential treatments. In addition to directing the Academic Medical Center’s diabetes unit and laboratory for Experimental Vascular Medicine, Dr. Nieuwdorp also works as a diabetes researcher at the VU University Medical Center Amsterdam and serves as a visiting professor at the University of Gothenborg’s Wallenberg laboratory. He received his M.D. from Urecht University and his Ph.D. from the University of Amsterdam.
Associate Professor, Department of Microbiology and Immunology, University of California, San Francisco
Dr. Turnbaugh is an Associate Professor in the Department of Microbiology and Immunology, the G.W. Hooper Research Foundation, and an Investigator in the Chan Zuckerberg Biohub, at the University of California, San Francisco. For over 15 years his research has focused on the metabolic activities performed by the trillion of microbes in the human body, using metagenomics and gnotobiotics to study the role of the gut microbiome in nutrition and pharmacology. He holds a Ph.D. in Microbial Genetics and Genomics from Washington University in St. Louis.
Work Together: We value each others’ perspectives and always act with integrity and transparency
Think Bigger, Think Differently: We take risks and challenge the status quo in pursuit of innovation
Learn & Challenge: We learn from success and failure, pushing beyond comfort zones
Keep Commitments: We make commitments and live up to them
Act with Urgency & Excellence: We are relentless in our drive to pursue rigorous science and pioneer new approaches that can transform lives